Celcuity Inc (nasdaq:CELC) Share Price

Company Profile

Business description
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Contact
16305 36th Avenue North
Suite 100
MinneapolisMN55446
USA
T: +1 763 392-0767
E: [email protected]
https://www.celcuity.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
155

Recommended

We see regulatory risk from both the US and Chinese governments.

Seth Goldstein, CFA | 25 October 2026

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,926.60	20.80	0.23%
CAC 40	7,840.67	57.85	0.74%
DAX 40	25,395.87	214.22	0.85%
Dow JONES (US)	52,215.16	652.82	-1.23%
FTSE 100	10,740.68	50.32	0.47%
HKSE	23,211.81	118.44	0.51%
NASDAQ	25,955.34	53.52	-0.21%
Nikkei 225	62,189.65	503.51	-0.80%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,623.68	39.75	-0.52%
S&P/ASX 200	8,809.90	14.70	0.17%
SSE Composite Index	3,697.52	7.04	0.19%